MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.85
-0.82
-5.61%
Opening 13:22 03/03 EST
OPEN
14.92
PREV CLOSE
14.67
HIGH
14.97
LOW
13.76
VOLUME
174.68K
TURNOVER
--
52 WEEK HIGH
29.40
52 WEEK LOW
3.590
MARKET CAP
218.23M
P/E (TTM)
-18.4338
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Enlivex Therapeutics Partners With Mount Sinai to Develop Allocetra With Checkpoint Inhibitors to Treat Solid Tumors
MT Newswires · 2d ago
Enlivex and Mount Sinai to explore potential of Allocetra with checkpoint inhibitors
Enlivex Therapeutics (ENLV) has partnered with Mount Sinai Health System in a new research collaboration for the development of Allocetra with checkpoint inhibitors.Under the terms of the agreement, the two
Seekingalpha · 2d ago
Enlivex and Mount Sinai Health System announce research collaboration deal
Enlivex Therapeutics (ENLV) and New York City's largest academic medical system Mount Sinai Health System announce a new research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors.Allocetra is a macrophage-re...
Seekingalpha · 2d ago
Enlivex And Mount Sinai Health System Announce Research Collaboration For Development Of Allocetra In Combination With Immune Checkpoint Inhibitors; Financial Details Not Disclosed
-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies -- Nes
Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies -- Nes · 2d ago
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
-- Collaboration aims to evaluate the potential of Allocetra(TM) in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies --
GlobeNewswire · 2d ago
BRIEF-Enlivex Receives Notice Of Allowance For Chinese Patent Application Covering Allocetra Immunotherapy
reuters.com · 02/22 14:14
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the &ldquo, Company&rdquo, )), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,
Benzinga · 02/22 13:08
Israel's Enlivex Therapeutics Secures China's Notice of Allowance Covering Allocetra Immunotherapy Patent
MT Newswires · 02/22 12:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENLV. Analyze the recent business situations of Enlivex Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENLV stock price target is 33.00 with a high estimate of 33.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 398.35K
% Owned: 2.53%
Shares Outstanding: 15.76M
TypeInstitutionsShares
Increased
1
12.17K
New
11
84.53K
Decreased
1
19.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.21%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Director
Shai Novik
Chief Executive Officer
Oren Hershkovitz
Founder/Chief Scientific Officer
Dror Mevorach
Chief Financial Officer
Shachar Shlosberger
Other
Odelia Ben-Shitrit
Director
Michel Habib
Director
Baruch Halpert
Director
Bernhard Kirschbaum
Director
Hyun Gyu Lee
Director
Sangwoo Lee
Director
Brian Schwartz
Independent Director
Gili Hart
Independent Director
Abraham Havron
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.